- Home
- ARMP vs WHWK Comparison
ARMP vs WHWK Comparison
Compare ARMP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMP | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.4M | 187.4M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ARMP | WHWK |
|---|---|---|
| Price | $4.40 | $4.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $7.50 |
| AVG Volume (30 Days) | 95.5K | ★ 430.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.02 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.40 | $1.68 |
| 52 Week High | $14.98 | $5.50 |
Technical Indicators
Market Signals| Indicator | ARMP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 63.41 |
| Support Level | $4.36 | $3.79 |
| Resistance Level | $5.60 | $4.84 |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 27.38 | 84.92 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.